# CUMBERLAND PHARMACEUTICALS INC (CPIX) — capital_return/special_dividend [announced]
Source: SEC API (secapi.ai) · situation sit_8a1e2c913cbca24cfd15 · retrieved 2026-08-11T15:59:13.665Z

## Overview
Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs, including Phase 2 clinical programs evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and Cancer Metastasis.

Cumberland Pharmaceuticals completed the sale of its portfolio of FDA-approved brands and related commercial organization to Apotex Health, the largest Canadian pharmaceutical company, for $100 million in cash at closing plus an additional $11 million in funding for inventory and transition services. The transaction was unanimously approved by Cumberland's Board of Directors and by shareholders with over 99% of voting shares in favor. Following the transaction, Cumberland transitioned into a development-stage biopharmaceutical organization focused on advancing differentiated medicines for rare diseases. Cumberland's Board of Directors authorized and declared a special cash dividend of $1.50 per share, paid on July 31, 2026, to shareholders of record as of July 23, 2026.

## Terms
- Counterparty: Apotex Health · Consideration: cash · Price/share: $1.5

## Key dates
- Announced 2026-07-13 · Record 2026-07-23 · Expected close 2026-07-31

## Timeline
- 2026-07-13 · 8-K (0001087294-26-000055): 8-K - CUMBERLAND PHARMACEUTICALS INC — *Cumberland Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative products for rare diseases, with a clinical pipeline including late-stage candidates such as ifetroban being evaluated in Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and Cancer Metastasis.* Cumberland Pharmaceuticals Inc. announced a special cash dividend of $1.50 per share of common stock, authorized and declared by the Board of Directors on July 13, 2026. The dividend is payable to shareholders of record as of July 23, 2026, with payment expected on or about July 31, 2026. The special dividend follows the closing of a strategic transaction with Apotex Health Corp., in which Cumberland received $100 million in cash for its line of FDA-approved products, plus up to $11 million in additional payments for product inventory and transitional support services. Following the transaction, the Company's tax advisors and refined financial projections indicated greater net cash than originally projected, prompting the Board to authorize the special dividend and a new $5 million open-market share repurchase program.
  https://www.sec.gov/Archives/edgar/data/1087294/0001087294-26-000055.txt
- 2026-08-04 · 8-K (0001087294-26-000058): 8-K - CUMBERLAND PHARMACEUTICALS INC — *Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs, including Phase 2 clinical programs evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and Cancer Metastasis.* Cumberland Pharmaceuticals completed the sale of its portfolio of FDA-approved brands and related commercial organization to Apotex Health, the largest Canadian pharmaceutical company, for $100 million in cash at closing plus an additional $11 million in funding for inventory and transition services. The transaction was unanimously approved by Cumberland's Board of Directors and by shareholders with over 99% of voting shares in favor. Following the transaction, Cumberland transitioned into a development-stage biopharmaceutical organization focused on advancing differentiated medicines for rare diseases. Cumberland's Board of Directors authorized and declared a special cash dividend of $1.50 per share, paid on July 31, 2026, to shareholders of record as of July 23, 2026.
  https://www.sec.gov/Archives/edgar/data/1087294/0001087294-26-000058.txt

## Citations
- 0001087294-26-000055 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000108729426000055
- 0001087294-26-000058 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000108729426000058